Lexaria Bioscience Completes Human Pilot Study for GLP-1 Drug Delivery
Lexaria Bioscience completes dosing of human pilot study #2, GLP-1-H24-2, to explore the tolerability and blood levels of semaglutide, a GLP-1 drug. The potential for effective oral delivery of GLP-1 drugs represents a vast global market potential.
This news matters as it showcases the potential for more effective oral delivery of GLP-1 drugs, which are used to address diabetes and weight loss. The study results could have a significant impact on the pharmaceutical industry and the treatment of these health conditions.
